

Denmark

The Ministry of Health +45 72269000 sum@sum.dk
Danish Health and Medicines Authority +45 72227400 sst@sst.dk

Flowchart of the pharmaceutical system

AUTHORISATION / CLASSIFICATION	European Medicines Agency (EMA) or Danish Medicines Agency (DKMA).	
	Task: Decision on authorization and registration Criteria: Quality, safety, efficacy etc. (Directive 2004/27/EC) and Danish Medicines Act, No. 1180 of 12 December 2005.	
PRICING	Danish Medicines Agency	
	Task: Categorises pharmaceuticals into POM, pharmacy-only OTC (Ha), OTC for limited free sale (Håndkøb, Hx) and OTC for general free sale (Frihandel, Hf) Criteria: Safety, suitability for self-medication, etc. (Danish Medicines Act, No. 1180 of 12 December 2005 and Executive Order on Prescriptions, No. 155 of 20 February 2007) Task: Decides if pharmaceuticals (generics) are substitutable or not substitutable Criteria: Active ingredient (ATC-5 level), bioequivalence, strength, pack size (Section 61 of the Danish Medicines Act, No. 1180 of 12 December 2005 and Note for Guidance on the investigation of bioavailability and bioequivalence (CPMP/EWP/QWP/1401/98)	
	Pricing is free. However, the DKMA has to be notified of the PPP. No permanent price control. Prices are set freely. DKMA publishes the consumer price and reimbursement price.	The companies can change prices every two weeks Prices are subject to subsequent control by the Danish Competition Council.

OUTPATIENT SECTOR

INPATIENT SECTOR

DKMA advised by the Reimbursement Committee

Task: Decides on eligibility for general or conditional reimbursement

Main criteria: Therapeutic value and cost-effectiveness according to the Danish Health Act, No. 546 of 24 June 2005 and Executive Order, No. 180 of 17 March 2005 on Reimbursement

